Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Interest & Investment Income (2022 - 2024)

Adial Pharmaceuticals' Interest & Investment Income history spans 3 years, with the latest figure at $53758.0 for Q4 2024.

  • For Q4 2024, Interest & Investment Income rose 378.91% year-over-year to $53758.0; the TTM value through Dec 2024 reached $178659.0, up 156.04%, while the annual FY2025 figure was $149567.0, 16.28% down from the prior year.
  • Interest & Investment Income for Q4 2024 was $53758.0 at Adial Pharmaceuticals, up from $50696.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $53758.0 in Q4 2024 and bottomed at $3472.0 in Q3 2022.
  • The 3-year median for Interest & Investment Income is $22801.0 (2024), against an average of $27878.3.
  • The largest annual shift saw Interest & Investment Income tumbled 76.53% in 2023 before it surged 395.27% in 2024.
  • A 3-year view of Interest & Investment Income shows it stood at $47821.0 in 2022, then crashed by 76.53% to $11225.0 in 2023, then soared by 378.91% to $53758.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Interest & Investment Income are $53758.0 (Q4 2024), $50696.0 (Q3 2024), and $51404.0 (Q2 2024).